An Exceptionally Potent Inhibitor of Human CD73

Abstract

We recently reported the initiation of a Phase I clinical trial with AB680, a potent human CD73 inhibitor, being developed for the treatment of solid tumors (NCT03677973). We undertook a detailed kinetic analysis of the interaction between human CD73 and AB680 to determine the mode of inhibition. We found AB680 to be a reversible, slow-onset competitive inhibitor of human CD73 with a <i>K</i>_i of 5 pM. Clinical candidates of this potency are uncommon and deserve special consideration during lead optimization.